Sanofi Looks To Build Stronger Alliances To Fuel R&D In Korea
This article was originally published in PharmAsia News
Marking the conclusion of a 2009 MOU, Sanofi signed a letter of intent with the Korean government to take R&D investments to a new level.
You may also be interested in...
SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said
SEOUL - Novartis signed a memorandum of understanding with Korea's Ministry for Health, Welfare and Family Affairs to invest $100 million (KRW 125 billion) over the next five years in the research and development of new drugs, scientific exchanges and collaboration in the life sciences
France's Sanofi Scans China And Korea For Partnerships And Acquisitions As Part Of Global R&D Transformation
BEIJING - As part of a radical redesign of its worldwide research and development model, France's Sanofi-Aventis is searching for potential biotechnology partners in China and South Korea, according to Marc Cluzel, who heads Sanofi's global R&D operations